FDA approves oritavancin (Kimyrsa) for treatment of adults with acute bacterial skin and skin structure infections caused by susceptible isolates of designated Gram-positive microorganisms, including MRSA

This lipoglycopeptide antibiotic is given as single, 1-hour infusion. An oritavancin-based product already on US market (Orbactiv), approved as alternative to vancomycin (VN), is infused over 3 hours. Approval of Kimyrsa based on trials showing it was as effective as VN for MRSA.

Source:

Biospace Inc.